NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 17th April 2009 Clopidogrel plus aspirin reduced the risk of a vascular composite end point compared with aspirin alone in people with AF who were at increased risk of […]
Category Archives: New medicines
NPC Archive Item: Update on new treatments for chronic idiopathic thrombocytopenic purpura
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 6th April 2009 Romiplostim▼ has recently been licensed for idiopathic thrombocytopenic purpura (ITP), and a new study of oral eltrombopag (not currently licensed in Europe) showed increased blood platelet […]
NPC Archive Item: Prasugrel▼ (Efient®) in patients with STEMI
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25th March 2009 A pre-specified subgroup analysis of the TRITON-TIMI 38 trial suggests that prasugrel ▼ may be more effective than clopidogrel in those with STEMI ACS undergoing PCI. Major […]
NPC Archive Item: DH clarify guidance around new daily dose treatments for impotence.
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 9th March 2009 The Department of Health’s (DH) guidance on treatment for impotence (HSC1999/148) recommends in paragraph 5 that one treatment per week will be appropriate for most patients […]
NPC Archive Item: Dronedarone in atrial fibrillation – does ATHENA provide the answers?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 5th March 2009 In the ATHENA trial of 4,628 patients with atrial fibrillation (AF) or flutter, dronedarone was more effective than placebo in reducing cardiovascular (CV) hospital admissions or […]
NPC Archive Item: Another biologic for the treatment of psoriasis
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25th February 2009 “Subcutaneous ustekinumab▼ (Stelara®) administered every twelve weeks was more effective than placebo for the treatment of moderate to severe psoriasis. This dosing frequency appears to maintain efficacy […]
NPC Archive Item: Incretin-based therapies in type 2 diabetes
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 24th February 2009 Madsbad S. Treatment of type 2 diabetes with incretin-based therapies. The Lancet 2009; 373:438-39 Incretin-based therapies may offer a new option in the treatment of type […]
NPC Archive Item: Oral telcagepant, a novel treatment for acute migraine
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 30th January 2009 Telcagepant 300mg improved relief of migraine pain and related symptoms two hours after a single dose as compared to placebo. The trial data suggests that the […]
NPC Archive Item: Tasimelteon for insomnia – early data in healthy people with an artificially disturbed sleep pattern.
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. In healthy people whose sleep pattern had been brought forward by five hours, a single dose of tasimelteon reduced the time to persistent sleep compared to placebo. It is […]
NPC Archive Item: Rivaroxaban (Xarelto®▼) reduces symptomatic VTE and death more than enoxaparin in patients undergoing hip or knee replacement
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Results from a pre-specified pooled analysis of the four, double-blind, double-dummy phase 3 (RECORD) studies have been presented as a conference abstract at the 50th Meeting of the American […]